Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Clin Cancer Res. 2013 Nov 11;20(3):754–763. doi: 10.1158/1078-0432.CCR-13-1960

Table 2.

Population pharmacokinetic parameters estimates with theory-based allometric exponents (100 bootstrap replications)

Parameter Description Unitsa Bootstrap
Estimate
(RSE%)
CL Clearance L/h/62kg NFM CL 11.4 (1.1)
V1 Central volume of distribution L/59kg NFM V 13.9 (6.6)
Q Inter-compartmental clearance L/h/62kg NFM CL 135.2 (7.2)
V2 Peripheral volume of distribution L/59kg NFM V 29.9 (3.0)
FFATCLb Fat fraction for clearance · 0.509 (42.8)
FFATVb Fat fraction for volume · 0.203 (51.6)
TM50CL PMA at 50% maturation · 45.7 (4.3)
HILLCL Hill coefficient for maturation · 2.3 (9.7)
FFEMV Fractional difference in total volume (V1+V2) in females · 1.07 (1.2)
FFEMDW Fractional difference in dosing weight in females · 1.08 (1.7)
FT1_CL Fraction of 0–6 h clearance >6 and <36 h · 0.932 (1.2)
FT2_CL Fraction of 0–6 h clearance ≥36 h · 0.919 (1.4)
Between Subject Variability (BSV)a
  TBW 0.166 (7.8)
  CL 0.215 (4.7)
  V1 0.410 (10.8)
  Q 0.922 (9.1)
  V2 0.120 (23.8)
Between Occasion Variability (BOV)b
  CL 0.113 (14.8)
  V1 0.244 (20.0)
  Q 0.577 (24.6)
  V2 0.212 (12.4)
  RUVADDc Additive residual unidentified variability ng/mL 26.2 (13.7)
  RUVPROPc Proportional residual unidentified variability · 0.0387 (12.8)
a

The NFM of 62 kg for CL and 59 kg for V correspond to allometrically scaled total body weights of 70 kg.

b

Bootstrap estimates for FFATCL and FFATV from ABW available data only.

c

Random effects are expressed as the square root of the estimated variance. BSV and BOV estimates are the apparent coefficient of variation of the variability.